El interés en corto de Johnson & Johnson da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Johnson & Johnson. Los datos de interés en corto se actualizan cada dos semanas.

Johnson & Johnson (NYSE:JNJ) Bolsa, Informe de interés en corto

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

JOHNSON & JOHNSON ORD

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) will release earnings results for its third quarter before the <a href="https://www.benzinga.com/quote/JNJ/earnings">opening bell on Tuesday, Oct. 15</a>.
Analysts expect the New Brunswick, New Jersey-based bank to report quarterly earnings at $2.21 per share, down from $2.66 per share in the year-ago period. Johnson &amp; Johnson projects to report revenue of $22.16 billion for the recent quarter, compared to $21.03 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Oct. 9, Johnson &amp; Johnson said it has completed acquisition of V-Wave.
Johnson &amp; Johnson shares gained 0.6% to close at $161.46 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $215 on Oct. 10. This analyst has an accuracy rate of 67%.</li>
<li>TD Cowen analyst Joshua Jennings maintained a Buy rating and cut the price target from $195 to $185 on July 18. This analyst has an accuracy rate of 61%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $167 to $169 on July 18. This analyst has an accuracy rate of 70%.</li>
<li>B of A Securities analyst Geoff Meacham maintained a Neutral rating and cut the price target from $180 to $170 on April 17. This analyst has an accuracy rate of 61%.</li>
<li>BMO Capital analyst James Fotheringham maintained a Market Perform rating and raised the price target from $57 to $59 on July 15. This analyst has an accuracy rate of 75%.</li>
</ul>
Considering buying JNJ stock? Here&#8217;s what analysts think:
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41304700/cvs-has-real-value-jim-cramer-says-micron-had-an-amazing-quarter">CVS Has &#8216;Real Value,&#8217; Jim Cramer Says: Micron Had An &#8216;Amazing&#8217; Quarter</a></li>
</ul>

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

High-rolling investors have positioned themselves bullish on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in JNJ often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Johnson &amp; Johnson. This is not a typical pattern.
The sentiment among these major traders is split, with 55% bullish and 44% bearish. Among all the options we identified, there was one put, amounting to $25,400, and 8 calls, totaling $745,068.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $180.0 for Johnson &amp; Johnson over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Johnson &amp; Johnson stands at 2036.56, with a total volume reaching 2,875.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Johnson &amp; Johnson, situated within the strike price corridor from $100.0 to $180.0, throughout the last 30 days.
<h3>Johnson &amp; Johnson Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728927943_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/17/26</td>
<td>$8.65</td>
<td>$8.4</td>
<td>$8.5</td>
<td>$180.00</td>
<td>$340.0K</td>
<td>6</td>
<td style="text-align: right;">400</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$1.67</td>
<td>$1.57</td>
<td>$1.57</td>
<td>$162.50</td>
<td>$109.9K</td>
<td>3.4K</td>
<td style="text-align: right;">912</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$12.9</td>
<td>$12.75</td>
<td>$12.75</td>
<td>$155.00</td>
<td>$102.0K</td>
<td>98</td>
<td style="text-align: right;">81</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$8.15</td>
<td>$7.95</td>
<td>$8.15</td>
<td>$165.00</td>
<td>$75.7K</td>
<td>2.1K</td>
<td style="text-align: right;">93</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.9</td>
<td>$61.45</td>
<td>$62.9</td>
<td>$100.00</td>
<td>$31.4K</td>
<td>21</td>
<td style="text-align: right;">5</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Having examined the options trading patterns of Johnson &amp; Johnson, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Johnson &amp; Johnson Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,681,824, with JNJ's price up by 0.06%, positioned at $161.55.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Expert Opinions on Johnson &amp; Johnson</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $199.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $215. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Johnson &amp; Johnson with a target price of $178. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $175. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $215. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $215. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Johnson &amp; Johnson, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On Johnson & Johnson

On Monday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)&nbsp;announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson &amp; Johnson&#8217;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) Stelara (ustekinumab)) in adults with moderately to severely <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41309730/lilly-reports-one-year-histologic-outcomes-in-phase-3-study-of-mirikizumab-compared-to-ustekinumab" rel="noreferrer noopener">active Crohn&#8217;s disease</a>.&nbsp;
The data showed that more patients achieved&nbsp;histologic response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41296978/novo-nordisk-eli-lilly-could-face-downward-pressure-despite-market-dominance-from-p" rel="noreferrer noopener">Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names</a>.
In patients with active histologic disease at baseline and with at least one prior biologic failure, mirikizumab also showed greater histologic response at Week 52 (56.5% versus 41.3%; p=0.0064) and endoscopic-histologic response at Week 52 (39.6% versus 27.8%; p=0.024).
The overall safety profile of mirikizumab in patients with moderately to severely active Crohn&#8217;s disease was consistent with the known safety profile in patients with ulcerative colitis (UC).
The frequency of serious adverse events was greater in placebo than mirikizumab. The most common adverse events were COVID-19, anemia, arthralgia, headache, upper respiratory tract infection, nasopharyngitis, and injection site reactions.&nbsp;
&#8220;As the first company to report rigorous histologic and endo-histologic&nbsp;outcomes in Crohn&#8217;s disease that align with a recent ECCO position statement, Lilly is setting a higher bar for the evaluation of long-term treatment response in inflammatory bowel disease. This includes more ambitious targets of mucosal healing, which we applied to compare mirikizumab&#8217;s histo-endoscopic effect to ustekinumab,&#8221; said&nbsp;Mark Genovese, senior vice president of Lilly Immunology development.
Mirikizumab is approved for moderately to severely active ulcerative colitis (UC) in adults and is marketed as Omvoh.
Mirikizumab has additional ongoing trials in UC, including a study in pediatric patients and a study to evaluate the long-term efficacy and safety of mirikizumab in adults.
Price Action: LLY stock is up 0.17% at $933.68 at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41312039/whats-going-on-with-us-listed-chinese-stocks-alibaba-baidu-nio-xpeng-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With US Listed Chinese Stocks Alibaba, Baidu, Nio, XPeng on Monday?</a></li>
</ul>

Biotech

Equities

Large Cap

Health Care

General

More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is set to announce its third quarter earnings on Oct. 15 before the market opens. Wall Street is expecting the pharmaceutical and healthcare giant to post earnings per share (EPS) of $2.21 and <a href="https://www.benzinga.com/quote/JNJ/earnings">revenue of $22.16 billion</a>. 
But while J&amp;J's numbers are in focus, recent headlines about its MedTech acquisitions and drug trial halts are stealing the spotlight.
<h2 class="wp-block-heading">MedTech Grows, Drug Trials Stumble</h2>
Johnson &amp; Johnson recently completed its <a href="https://www.benzinga.com//node/41247724">acquisition of V-Wave</a>, adding a minimally invasive cardiovascular treatment to its MedTech portfolio. The Ventura Interatrial Shunt is expected to strengthen J&amp;J's position in tackling heart failure, but the acquisition comes with a short-term cost. The company has warned that this move will dilute adjusted EPS by around 24 cents in 2024 and 6 cents in 2025, an update they'll likely address in Tuesday&#8217;s earnings report.
On the flip side, the company had to <a href="https://www.benzinga.com//node/41189182">discontinue its Phase 3 SunRISe-2 trial</a>, which was investigating a treatment for muscle-invasive bladder cancer. The trial didn't show superiority over chemoradiation, leading to its early termination, though J&amp;J remains optimistic about the future of its TARIS platform, forecasting a $5 billion potential.
<h2 class="wp-block-heading">The Charts Are Sending Mixed Signals</h2>
Despite some positive news in the MedTech arena, Johnson &amp; Johnson&#8217;s stock has had a relatively stagnant year, up just 0.93% year-to-date and only 2.49% over the past year. But in the past six months, the stock has seen a 9.40% rise, reflecting a slow but steady recovery.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="455" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14084639/Screenshot-2024-10-14-at-4.15.57-PM.png" alt="" class="wp-image-593811" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14084639/Screenshot-2024-10-14-at-4.15.57-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14084639/Screenshot-2024-10-14-at-4.15.57-PM-300x217.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101424&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
At its current price of $161.46, JNJ stock is just above its eight-day simple moving average of $160.48, a positive sign. However, the stock is lagging behind its 20-day and 50-day simple moving averages, sitting at $162.32 and $162.53, respectively. This signals some underlying selling pressure that may persist in the near term.
Read Also: <a href="https://www.benzinga.com//node/41279657">What Analysts Are Saying About Johnson &amp; Johnson Stock</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="455" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14084649/Screenshot-2024-10-14-at-4.16.08-PM.png" alt="" class="wp-image-593812" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14084649/Screenshot-2024-10-14-at-4.16.08-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14084649/Screenshot-2024-10-14-at-4.16.08-PM-300x217.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101424&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The Moving Average Convergence/Divergence (MACD) indicator at a negative 0.72 leans toward bearishness, hinting at continued downward pressure. Meanwhile, JNJ stock's Relative Strength Index (RSI) of 47.83 suggests the stock is in neutral territory.
The Bollinger Bands show a range between $157.98 and $168.05, with JNJ stock nestled in the lower bearish band. This positioning could suggest that the stock is poised for a bounce, but given the selling pressure, caution is warranted.
<h2 class="wp-block-heading">Can Q3 Earnings Change The Tune?</h2>
All eyes will be on J&amp;J's third-quarter earnings report. Investors are particularly interested in any updates to the company's guidance following the V-Wave acquisition and the ongoing performance of its MedTech and Innovative Medicine segments.
Johnson &amp; Johnson's charts may not be flashing strong bullish signals, but its strategic moves in MedTech and future product pipeline could offer long-term growth potential. 
Investors will have to weigh the upcoming earnings report to see if J&amp;J stock can shake off recent pressures and revitalize its performance.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/41290528">World&#8217;s Third-Largest OTC Player Sanofi&#8217;s Consumer Health Unit Nears $16B Deal With Clayton Dubilier &amp; Rice</a></li>
</ul>
Photo: Shutterstock

Technicals

Previews

Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals

As Columbus Day approaches, investors and market participants are preparing for a unique trading environment. This U.S. holiday, observed on Monday, October 14, 2024, will see a mix of open and closed financial markets, impacting trading activities.
Columbus Day, a federal holiday commemorating the 1492 landing of Christopher Columbus in North America, will see the New York Stock Exchange and the Nasdaq Stock Market operating as usually. Over-the-counter (OTC) markets will also remain open, while bond markets will be closed. The U.S. Postal Service and the Federal Reserve will not operate, and many banks will follow suit. 
In some states, the day is also recognized as Indigenous People&#8217;s Day, celebrating the resilience of Indigenous communities.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41299648/bitcoin-ethereum-dogecoin-see-friday-gains-but-trader-warns-59-000-must-hold-no-major-move?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin See Friday Gains, But Trader Warns &#8216;$59,000 Must Hold, No Major Moves Expecte</a>
Internationally, trading will continue as usual in most markets, except for the Toronto Stock Exchange, which will close in observance of Canada&#8217;s Thanksgiving Day. 
Investors should brace for a busy week with earnings reports from major companies such as UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), and Taiwan Semiconductor Manufacturing Company Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>). Additionally, key economic data releases, including jobless claims, retail sales, and housing starts, will provide insights into the current state of the economy.
Price Action: On Monday during pre-market hours, at the time of writing, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was trading slight higher, around 0.22% while Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was up by 0.32%, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41288392/justin-biebers-2024-crypto-returns-discover-how-much-the-pop-icon-made-on-his-ethereum-inv?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Justin Bieber&#8217;s 2024 Crypto Returns – Discover How Much The Pop Icon Made On His Ethereum Investment!</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Columbus Day: Is Stock Market Open Today?

Financial giants have made a conspicuous bearish move on Johnson &amp; Johnson. Our analysis of options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) revealed 8 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 75% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $229,594, and 4 were calls, valued at $214,282.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $155.0 to $175.0 for Johnson &amp; Johnson over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Johnson &amp; Johnson's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Johnson &amp; Johnson's significant trades, within a strike price range of $155.0 to $175.0, over the past month.
<h3>Johnson &amp; Johnson 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728661685_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$5.7</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$165.00</td>
<td>$109.4K</td>
<td>376</td>
<td style="text-align: right;">199</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.25</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$175.00</td>
<td>$75.0K</td>
<td>124</td>
<td style="text-align: right;">124</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.2</td>
<td>$2.08</td>
<td>$2.16</td>
<td>$162.50</td>
<td>$57.2K</td>
<td>3.2K</td>
<td style="text-align: right;">51</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$1.25</td>
<td>$1.1</td>
<td>$1.13</td>
<td>$170.00</td>
<td>$56.5K</td>
<td>314</td>
<td style="text-align: right;">504</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$160.00</td>
<td>$53.0K</td>
<td>6.7K</td>
<td style="text-align: right;">214</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Having examined the options trading patterns of Johnson &amp; Johnson, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Johnson &amp; Johnson Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,628,630, with JNJ's price up by 0.81%, positioned at $161.81.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 4 days.</li>
</ul>
<h3>What Analysts Are Saying About Johnson &amp; Johnson</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $199.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $175. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Johnson &amp; Johnson, targeting a price of $178. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $215. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $215. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $215. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Johnson &amp; Johnson with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on JNJ Options

On Friday, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) said it is negotiating with Clayton Dubilier &amp; Rice (CD&amp;R) to potentially sell a 50% controlling stake in Opella, its <a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35458838/sanofi-goes-the-rival-way-plans-separation-of-consumer-healthcare-unit" rel="noreferrer noopener">consumer healthcare business</a>.
According to the Bloomberg report, the <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-10-10/cd-r-said-near-15-billion-deal-for-sanofi-consumer-health-unit" rel="noreferrer noopener">deal</a> could be valued at about 15 billion euros ($16.4 billion), making it one of the largest European transactions this year. Sanofi is likely to retain a minority stake in the Opella business.
In October 2023,&nbsp;Sanofi announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35458838/sanofi-goes-the-rival-way-plans-separation-of-consumer-healthcare-unit" rel="noreferrer noopener">pipeline and cut costs</a>.
Sanofi said the spinoff would allow it to increase its focus on innovative medicines and vaccines.
As per a Bloomberg report, two private equity firms,&nbsp;Clayton Dubilier &amp; Rice and&nbsp;PAI Partners, made separate bids for Sanofi&#8217;s <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41021471/private-equity-firms-circle-sanofis-consumer-health-business-amid-potential-spinoff" rel="noreferrer noopener">consumer health division</a>.
If these <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-10-11-06-30-00-2961805" rel="noreferrer noopener">discussions</a> lead to a positive outcome, any agreement would be conditional on completing the necessary social processes.
Further updates on the potential separation of Opella will be provided in due course when a decision is made.
Headquartered in France, Opella employs over 11,000 people, operates in 100 countries, and manages 13 manufacturing sites and four research and innovation centers.
With a portfolio of 100 leading brands, including Allegra, Doliprane, Novanight, Icy Hot, and Dulcolax, Opella is the world&#8217;s third-largest company in the over-the-counter and vitamins, minerals, and supplements market, serving over 500 million consumers worldwide.
Opella&#8217;s journey to independence aligns with Sanofi&#8217;s strategy to focus on innovative medicines and vaccines.
Opella already operates today as a standalone business unit within Sanofi, with dedicated R&amp;D, production, and digital resources.
Goldman Sachs Group Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) and&nbsp;Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) said they were preparing to arrange more than $6.5 billion (6 billion euros) in debt financing for potential buyers interested in acquiring&nbsp;Sanofi&#8217;s <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39755459/sanofis-20b-consumer-health-unit-sale-goldman-sachs-morgan-stanley-line-up-6-5b-financing" rel="noreferrer noopener">consumer health division</a>.
Last year, Sanofi initiated talks with Rothschild &amp; Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at <a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/35823034/major-buyout-firms-eye-sanofis-consumer-health-division-spinoff-valued-over-20b" rel="noreferrer noopener">over $20 billion</a>.&nbsp;
Other potential bidders who <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39502197/sanofi-looks-to-sell-20b-icy-hot-division-likely-bidders-include-advent-pai-partners-blackstone-c" rel="noreferrer noopener">circled the deal include</a> Advent International, Blackstone Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), CVC Capital Partners Plc, and&nbsp;TPG Inc.
Separating the consumer health unit would align Sanofi with industry peers.&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) have also divested their consumer divisions&nbsp;Haleon Plc&nbsp;
(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) and Kenvue Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>), respectively, to focus on&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35458838/sanofi-goes-the-rival-way-plans-separation-of-consumer-healthcare-unit" rel="noreferrer noopener">next-generation therapies</a>.
Price Action: At last check on Friday, SNY stock was up 0.11% at $54.83 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41289207/wells-fargo-q3-earnings-lower-profit-on-squeezed-interest-income-but-investment-banking-fees-provid" target="_blank" rel="noreferrer noopener">Wells Fargo Q3 Earnings: Lower Profit On Squeezed Interest Income, But Investment Banking Fees Provide Cushion</a></li>
</ul>
Image by HJBC via Shutterstock

Media

KVUE

World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice

17 analysts have expressed a variety of opinions on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Johnson &amp; Johnson, presenting an average target of $193.94, a high estimate of $215.00, and a low estimate of $150.00. This current average has decreased by 0.6% from the previous average price target of $195.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1728586818_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Johnson &amp; Johnson by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$178.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Narumi Nakagiri</td>
<td>Daiwa Capital</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$155.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$169.00</td>
<td>$167.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Johnson &amp; Johnson. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Johnson &amp; Johnson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Johnson &amp; Johnson's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>All You Need to Know About Johnson &amp; Johnson</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Johnson &amp; Johnson: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Johnson &amp; Johnson's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 4.31%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 20.88%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 6.62%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Johnson &amp; Johnson's ROA excels beyond industry benchmarks, reaching 2.65%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.58.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Johnson & Johnson Stock

Cantor Fitzgerald analyst Louise Chen reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Overweight and maintains $215 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors and industry enthusiasts. In this article, we will delve into an extensive industry comparison, evaluating Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) in comparison to its major competitors within the Pharmaceuticals industry. By analyzing critical financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
<h3>Johnson &amp; Johnson Background</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson &amp; Johnson</td>
<td>24.30</td>
<td>5.41</td>
<td>4.56</td>
<td>6.62%</td>
<td>$7.8</td>
<td>$15.58</td>
<td>4.31%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>113.27</td>
<td>61.06</td>
<td>21.36</td>
<td>22.5%</td>
<td>$4.12</td>
<td>$9.13</td>
<td>35.98%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>39.59</td>
<td>31.45</td>
<td>13.79</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc</td>
<td>20.42</td>
<td>6.41</td>
<td>4.50</td>
<td>13.0%</td>
<td>$7.45</td>
<td>$12.37</td>
<td>7.16%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>37.62</td>
<td>6.08</td>
<td>4.93</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>23.65</td>
<td>5.61</td>
<td>4.88</td>
<td>7.97%</td>
<td>$5.25</td>
<td>$9.7</td>
<td>9.6%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>29.91</td>
<td>1.73</td>
<td>2.66</td>
<td>1.53%</td>
<td>$2.03</td>
<td>$7.97</td>
<td>6.53%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>37.29</td>
<td>17.35</td>
<td>9.79</td>
<td>12.45%</td>
<td>$0.97</td>
<td>$1.69</td>
<td>8.3%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>13.63</td>
<td>4.36</td>
<td>1.77</td>
<td>8.32%</td>
<td>$2.31</td>
<td>$5.76</td>
<td>9.84%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>45.03</td>
<td>0.86</td>
<td>1.52</td>
<td>1.26%</td>
<td>$388.51</td>
<td>$821.04</td>
<td>14.11%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>19.84</td>
<td>3.74</td>
<td>3.82</td>
<td>4.84%</td>
<td>$21.72</td>
<td>$46.34</td>
<td>13.87%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.21</td>
<td>1.76</td>
<td>1.93</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>40.65</td>
<td>8.05</td>
<td>8.93</td>
<td>6.14%</td>
<td>$0.04</td>
<td>$0.16</td>
<td>39.15%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>4.65</td>
<td>32.24</td>
<td>0.73</td>
<td>203.12%</td>
<td>$0.43</td>
<td>$0.94</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>16.69</td>
<td>2.01</td>
<td>3.08</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>32.89</td>
<td>13.05</td>
<td>5.98</td>
<td>22.33%</td>
<td>$33.8</td>
<td>$70.34</td>
<td>13.27%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Upon closer analysis of Johnson &amp; Johnson, the following trends become apparent: 
<ul>
<li>
The stock's Price to Earnings ratio of 24.3 is lower than the industry average by 0.74x, suggesting potential value in the eyes of market participants.
</li>
<li>
With a Price to Book ratio of 5.41, significantly falling below the industry average by 0.41x, it suggests undervaluation and the possibility of untapped growth prospects.
</li>
<li>
Based on its sales performance, the stock could be deemed undervalued with a Price to Sales ratio of 4.56, which is 0.76x the industry average.
</li>
<li>
With a Return on Equity (ROE) of 6.62% that is 15.71% below the industry average, it appears that the company exhibits potential inefficiency in utilizing equity to generate profits.
</li>
<li>
Compared to its industry, the company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.8 Billion, which is 0.23x below the industry average, potentially indicating lower profitability or financial challenges.
</li>
<li>
The company has lower gross profit of $15.58 Billion, which indicates 0.22x below the industry average. This potentially indicates lower revenue after accounting for production costs.
</li>
<li>
The company is witnessing a substantial decline in revenue growth, with a rate of 4.31% compared to the industry average of 13.27%, which indicates a challenging sales environment.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728572443_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio indicates the proportion of debt and equity used by a company to finance its assets and operations.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By analyzing Johnson &amp; Johnson in relation to its top 4 peers based on the Debt-to-Equity ratio, the following insights can be derived:
<ul>
<li>
Johnson &amp; Johnson exhibits a stronger financial position compared to its top 4 peers in the sector, as indicated by its lower debt-to-equity ratio of 0.58.
</li>
<li>
This suggests that the company has a more favorable balance between debt and equity, which can be seen as a positive aspect for investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Johnson &amp; Johnson in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to its peers, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest underperformance relative to industry standards. This may signal a need for further investigation into the company's operational efficiency and growth strategies.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Into Johnson &amp; Johnson's Performance Versus Peers In Pharmaceuticals Sector

XtalFold Validated In Over 30 Programs Since Launch, Facilitating Innovation In Antigen Design, Epitope Identification, And Bispecifics Design

Ailux Biologics, A Division Of XtalPi, Enters License Agreement With Janssen Biotech To Utilize XtalFold AI Platform For Biologics Discovery And Engineering

TREMFYA&#xAE;&nbsp;is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease
TREMFYA&#xAE; is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and biologic-refractory&nbsp;
Ninety percent more biologic-naïve&nbsp;patients and three times more biologic-refractory patients with ulcerative colitis achieved endoscopic remission with TREMFYA&#xAE;&nbsp;
VIENNA, Austria, Oct. 10, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)&nbsp;today announced TREMFYA&#xAE; (guselkumab) data in both Crohn's disease (CD) and ulcerative colitis (UC) showing high rates of endoscopic remission in both biologic-naïve and biologic-refractory patients (including UC patients refractory to JAK inhibitors), indicating a normal appearance of intestinal mucosa.1,2 These subgroup analyses are from pooled data from the Phase 3 GALAXI 2 &amp; 3 studies of TREMFYA&#xAE; in adults with moderately to severely active CD and the Phase 3 QUASAR maintenance study of TREMFYA&#xAE; in adults with moderately to severely active UC. These findings are among 19 Johnson &amp; Johnson abstracts being presented at the United European Gastroenterology (UEG) Week 2024. TREMFYA&#xAE;&nbsp;is under review for the treatment of adults with moderately to severely active UC and CD by the European Medicines Agency (EMA).&nbsp;

Johnson & Johnson Announces TREMFYA Demonstrates Results Across Biologic-Naïve And Biologic-Refractory Patients In Crohn's Disease And Ulcerative Colitis

Guidance

Johnson & Johnson Completes V-Wave Acquisition; Expects Transaction To Dilute Adj. EPS By ~$0.24 In 2024 And ~$0.06 In 2025, Will Provide Update To 2024 Outlook In Oct. 15 Earnings Report

RBC Capital analyst Shagun Singh maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and raises the price target from $175 to $178.

RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $178

Monday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma (MIBC) patients who are not receiving radical cystectomy.
Following an Independent Data Monitoring Committee <a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-the-sunrise-2-study" rel="noreferrer noopener">recommendation</a> and pre-specified interim analysis, <a target="_blank" href="https://clinicaltrials.gov/study/NCT04658862?term=SunRISe-2&amp;rank=1" rel="noreferrer noopener">SunRISe-2</a> was discontinued for not showing superiority versus chemoradiation.
&#8220;We remain confident in the TARIS platform having over $5 billion potential,&#8221; Johnson &amp; Johnson notes.
Data from the SunRISe-4 study recently&nbsp;<a target="_blank" href="https://www.jnj.com/media-center/press-releases/neoadjuvant-tar-200-plus-cetrelimab-nearly-doubles-the-pathological-complete-response-rate-compared-to-cetrelimab-alone-in-patients-with-muscle-invasive-bladder-cancer" rel="noreferrer noopener">presented</a> at the 2024 European Society for Medical Oncology Congress show the potential of TAR-200 in MIBC.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41189182/johnson-johnson-ends-phase-2-study-for-dengue-antiviral-amid-r-d-reprioritization" rel="noreferrer noopener">Johnson &amp; Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&amp;D Reprioritization</a>.
The company says it is on target for the FDA filing of TAR-200 monotherapy (SunRISe-1) in non-muscle invasive bladder cancer in early 2025, with the&nbsp;<a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT05714202?term=05714202&amp;draw=2&amp;rank=1" rel="noreferrer noopener">SunRISe-3</a> and&nbsp;<a target="_blank" href="https://clinicaltrials.gov/study/NCT06211764?term=sunrise-5&amp;rank=1" rel="noreferrer noopener">SunRISe-5</a> studies underway.
Johnson &amp; Johnson is set to release its third quarter 2024 earnings next Wednesday, 15 October. As per data from Benzinga Pro, the analysts estimate adjusted EPS of $2.20 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">revenue of $22.13 billion</a>.
Goldman Sachs has reiterated its Neutral rating while increasing the price target <a target="_blank" href="https://www.benzinga.com/quote/JNJ/analyst-ratings" rel="noreferrer noopener">from $155 to $162</a>.
The analyst expects the pharma giant to report third-quarter results in line with consensus expectations on the top line with revenues of $22.26 billion, with year-over-year growth of +4.4%, representing a slight incremental deceleration in the pace of growth from the first half of 2024.
Goldman Sachs&#8217; outlook for the quarter remains mostly consistent overall, with a slight upward revision to the Innovative Medicine forecast compared to estimates following the second-quarter results. This improvement is attributed to potentially less impact from introducing biosimilar Stelara in Europe during the third quarter.
This adjustment helps counterbalance a modest reduction in the MedTech segment forecasts.
&#8220;We expect management to reiterate guidance on the FY25 revenue growth outlook of +3% or more, and for longer-term targets (Innovative Medicine growth at a CAGR of 5-7% from 2025-30, and growth at the upper end of the 5-7% CAGR for MedTech from 2023-27) to remain intact,&#8221; the analyst writes.
Price Action: JNJ stock is down 0.21% at $159.20 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41234724/mercks-mumps-vaccine-controversy-class-action-lawsuit-alleges-anticompetitive-behavior-court-shie" target="_blank" rel="noreferrer noopener">Merck&#8217;s Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability</a></li>
</ul>
Photo by Tada Images via Shutterstock

Analyst Color

What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12108928?requestToken=eyJzdWIiOiI0N2NmZDc2OC05MjVlLTQzM2ItOGUyNi0xZjQyNDYxMDIyN2EiLCJ2ZXIiOiI1ZTZlZjY4OC1jYjkwLTQ1MWQtYWRmZS1kYTViYTA4MTRlY2UiLCJleHAiOjB9" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12108928?requestToken=eyJzdWIiOiI0N2NmZDc2OC05MjVlLTQzM2ItOGUyNi0xZjQyNDYxMDIyN2EiLCJ2ZXIiOiI1ZTZlZjY4OC1jYjkwLTQ1MWQtYWRmZS1kYTViYTA4MTRlY2UiLCJleHAiOjB9">https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12108928?requestToken=eyJzdWIiOiI0N2NmZDc2OC05MjVlLTQzM2ItOGUyNi0xZjQyNDYxMDIyN2EiLCJ2ZXIiOiI1ZTZlZjY4OC1jYjkwLTQ1MWQtYWRmZS1kYTViYTA4MTRlY2UiLCJleHAiOjB9</a>

Verb Surgical Granted US Patent # 12,108,928 B2 For MACHINE-LEARNING-BASED VISUAL-HAPTIC SYSTEM FOR ROBOTIC SURGICAL PLATFORMS

Dean Omar Branham Shirley represents family of deceased woman
A Circuit Court in Cook County, Ill., has denied a request by Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) for a new trial in a mesothelioma lawsuit decided in April, upholding a jury verdict and award of $45 million in the asbestos-related death of a mother of six.
Johnson &amp; Johnson raised multiple issues in its motion for a new trial, but in each case, the court either found for the plaintiff or determined that any issue did not substantially prejudice the jury.
The decision from Judge Patrick J. Sherlock means the jury's verdict in the case filed by the children of Theresa Garcia will stand.

Legal

A Circuit Court In Cook County, Illinois Has Denied A Request By Johnson & Johnson For A New Trial In A Mesothelioma Lawsuit Decided In April; Upholding A Jury Verdict And Award Of $45M

On Friday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-65.
The <a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-to-discontinue-phase-2-field-study-evaluating-investigational-antiviral-for-the-prevention-of-dengue" rel="noreferrer noopener">decision</a> to discontinue this study is part of a strategic reprioritization of the company&#8217;s Communicable Diseases research and development (R&amp;D) portfolio. No safety issues were identified.
Efficacy data from the Phase 2 field study will be available once the final data analyses, which are now underway, are complete.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41143856/johnson-johnsons-erleada-shows-improved-overall-survival-in-prostate-cancer-patients-compared-to-" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer&#8217;s Drug</a>.
Mosnodenvir (formerly JNJ-1802) was shown to be safe and well tolerated in previous Phase 1 and Phase 2a clinical studies.
In October 2023, results from the Phase 2a human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo.
The study <a target="_blank" href="https://www.jnj.com/media-center/press-releases/janssen-announces-promising-antiviral-activity-against-dengue-in-a-phase-2a-human-challenge-model" rel="noreferrer noopener">evaluated</a> different dosing regimens – low, medium or high – of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults.
All participants received daily doses of JNJ-1802 or a placebo over 26 days, during which they were challenged with DENV-3 on day 5.
All participants were monitored over 85 days. The study found a dose-dependent antiviral effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo and was safe and well-tolerated.
In May, Takeda Pharmaceutical Co Ltd&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) dengue vaccine&nbsp;received World Health Organization&#8217;s (WHO) prequalification.&nbsp;
TAK-003 is the second dengue vaccine to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/04/31935884/united-nations-specialized-agency-in-preliminary-talks-with-takeda-for-dengue-vaccine-currently-u" rel="noreferrer noopener">be prequalified by WHO</a>.&nbsp;
WHO recommended using TAK-003 in children aged 6–16 in settings with high dengue burden <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38853309/takedas-dengue-vaccine-gets-who-approval-eligible-for-un-procurement" rel="noreferrer noopener">and transmission intensity</a>.&nbsp;
Price Action: JNJ stock is down 0.60% at $159.53 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41187920/lucid-air-electric-vehicles-join-blink-chargings-envoy-program-details" target="_blank" rel="noreferrer noopener">Lucid Air Electric Vehicles Join Blink Charging&#8217;s Envoy Program: Details</a>.</li>
</ul>
Photo via Shutterstock

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization

Johnson & Johnson To Discontinue Phase 2 Field Study Evaluating Investigational Antiviral For Prevention Of Dengue; Decision To Discontinue Study Part Of A Strategic Reprioritization Of Company's Communicable Diseases R&D Portfolio; No Safety Issues Identified To Date In Phase 2 Field Study

Financial giants have made a conspicuous bearish move on Johnson &amp; Johnson. Our analysis of options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) revealed 8 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 75% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $294,749, and 4 were calls, valued at $638,264.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $155.0 and $162.5 for Johnson &amp; Johnson, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Johnson &amp; Johnson options trades today is 2676.43 with a total volume of 5,256.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Johnson &amp; Johnson's big money trades within a strike price range of $155.0 to $162.5 over the last 30 days.
<h3>Johnson &amp; Johnson Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727889417_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.61</td>
<td>$2.5</td>
<td>$2.52</td>
<td>$162.50</td>
<td>$504.0K</td>
<td>761</td>
<td>2.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$1.23</td>
<td>$1.22</td>
<td>$1.23</td>
<td>$160.00</td>
<td>$128.4K</td>
<td>1.0K</td>
<td>380</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$1.29</td>
<td>$1.28</td>
<td>$1.28</td>
<td>$160.00</td>
<td>$103.8K</td>
<td>1.0K</td>
<td>2.2K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/25/24</td>
<td>$2.92</td>
<td>$2.91</td>
<td>$2.92</td>
<td>$162.50</td>
<td>$55.7K</td>
<td>30</td>
<td>345</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$11.0</td>
<td>$10.85</td>
<td>$10.85</td>
<td>$155.00</td>
<td>$45.5K</td>
<td>3.2K</td>
<td>95</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Having examined the options trading patterns of Johnson &amp; Johnson, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Trading volume stands at 2,469,466, with JNJ's price down by -0.48%, positioned at $161.21.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
<h3>What The Experts Say On Johnson &amp; Johnson</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $207.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $175. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $215. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $215. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $215. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $215.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Johnson &amp; Johnson options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Johnson & Johnson's Options: A Look at What the Big Money is Thinking

Wall Street Breakfast: The Week Ahead

Earnings week ahead: BAC, GS, JNJ, TSM, UNH, ABT, UAL, NFLX, PG, AXP and more

Healthcare giant Johnson & Johnson ($JNJ) is gearing up to release its third-quarter 2024 financials on October 15. Wall Street analysts expect the...

Johnson & Johnson (JNJ) Q3 Pre-Earnings: Here's What to Expect

This week, several major companies will be reporting earnings. Among them are Netflix (NFLX), Bank of America (BAC), Johnson & Johnson (JNJ), Citig...

Options Volatility and Implied Earnings Moves This Week, October 15 – October 18, 2024

Lilly reports positive data for Omvoh versus Stelara in Crohn's

7 out of 8 S&P 500 companies deliver EPS wins this week - Earnings scorecard

Shares of drug maker Eli Lilly ($LLY) were little changed at the time of writing despite announcing results from its Phase 3 VIVID-1 trial, which s...

Eli Lilly's (NYSE:LLY) Crohn's Disease Drug Outperforms JNJ's Version

Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana.

Healthcare Sector Update: Life In The Slow Lane While We Wait For Biotech Bounce

Johnson & Johnson Q3 Preview: Decline in profit is in the cards

IYH: Healthcare Dashboard For October

ABBV

ALKS

ALLY

AMGN

ASML

COLL

ERIC

EXEL

FITB

GEHC

HBAN

HRMY

IBKR

INFY

INVA

IRDM

ISRG

JBHT

KARO

NFLX

REGN

RSPH

SCHW

SCYX

STLD

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line

Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting

Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned

ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer

Small Cap

Opinion

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Chicago Court Upholds $45 Million Mesothelioma Verdict Against Johnson & Johnson

Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference

Johnson & Johnson Completes Acquisition of V-Wave

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis

Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference

ANVS

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Johnson & Johnson

Interés en corto

Johnson & Johnson (NYSE:JNJ) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL